[av_slideshow_full size='featured' min_height='0px' stretch='' animation='slide' conditional_play='' autoplay='false' interval='5' control_layout='av-control-default' src='' attachment='' attachment_size='' position='top left' repeat='no-repeat' attach='scroll' av_uid='av-jkzq3f8p']
[av_slide_full slide_type='image' id='186' video='http://' mobile_image='' fallback_link='http://' video_format='' video_ratio='16:9' title='PrEP' custom_title_size='34' custom_content_size='27' caption_pos='caption_bottom caption_bottom_framed caption_framed' link_apply='' link='lightbox' link_target='' button_label='Click me' button_color='light' link1='manually,http://' link_target1='' button_label2='Click me' button_color2='light' link2='manually,http://' link_target2='' font_color='' custom_title='' custom_content='' overlay_opacity='0.5' overlay_color='' overlay_pattern='' overlay_custom_pattern='' av-medium-font-size-title='' av-small-font-size-title='' av-mini-font-size-title='' av-medium-font-size='' av-small-font-size='' av-mini-font-size='' av_uid='av-8tsxx']
Sanguen offers access to the anti-retroviral medication PrEP to persons at risk of HIV infection.
[/av_slide_full]
[/av_slideshow_full]

[av_textblock size='' font_color='' color='' av-medium-font-size='' av-small-font-size='' av-mini-font-size='' av_uid='av-jneyc0zc' admin_preview_bg='']
<h2 style="text-align: center;">WHAT IS HIV PrEP?</h2>
<p>PrEP is the administration of a combination anti-retroviral medication (tenofovir DF/ emtricitabine 300/200 mg, Truvada) to HIV-uninfected individuals at high and ongoing risk of HIV acquisition to prevent HIV.</p>

<h3 style="text-align: center;">Who Should Be Considered For HIV PrEP?</h3>
    <ul>
     <li>PrEP is recommended for MSM and trans-F with a HIRI-MSM score > 10 - 11</li>
     <li>PrEP is recommended for MSM and trans-F who have had condomless anal intercourse within 12 months AND have infectious syphilis or rectal STI OR have recurrent use of HIV post-exposure prophylaxis OR have an ongoing sexual relationship with HIV + partner with viral load > 40 copies/mL </li>

    <li>PrEP is recommended for the HIV-negative partner in a heterosexual serodiscordant relationship where condomless anal or vaginal sex is occurring in the context of a substantial or non-negligible risk of transmission (negligible risk is defined as some with a viral load < 40 copies/mL AND no known STIs present at time of exposure)</li>

    <li>PrEP may be considered for individuals who use injection drugs if they share injection drug use paraphernalia</li>


<h3 style="text-align: center;">What Is The HIRI-MSM?</h3>
The HIV Incidence Risk Index for MSM (HIRI-MSM) is a validated risk tool. A score of 10 corresponds with a 2% annual risk of HIV acquisition; a score of 25 corresponds with a 7% annual risk.

[/av_textblock]

